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Abstract
Background: GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich
protein (GLURP) that mediates an immune response against the blood stage of the parasite. Two previous phase I clinical
trials, one in naı¨ve European adults and one in malaria-exposed Gabonese adults showed that GMZ2 was well tolerated and
immunogenic. Here, we present data on safety and immunogenicity of GMZ2 in one to five year old Gabonese children, a
target population for future malaria vaccine efficacy trials.
Methodology/Principal Findings: Thirty children one to five years of age were randomized to receive three doses of either
30 mg or 100 mg of GMZ2, or rabies vaccine. GMZ2, adjuvanted in aluminum hydroxide, was administered on Days 0, 28 and
56. All participants received a full course of their respective vaccination and were followed up for one year. Both 30 mg and
100 mg GMZ2 vaccine doses were well tolerated and induced antibodies and memory B-cells against GMZ2 as well as its
antigenic constituents MSP3 and GLURP. After three doses of vaccine, the geometric mean concentration of antibodies to
GMZ2 was 19-fold (95%CI: 11,34) higher in the 30 mg GMZ2 group than in the rabies vaccine controls, and 16-fold (7,36)
higher in the 100 mg GMZ2 group than the rabies group. Geometric mean concentration of antibodies to MSP3 was 2.7-fold
(1.6,4.6) higher in the 30 mg group than in the rabies group and 3.8-fold (1.5,9.6) higher in the 100 mg group. Memory B-cells
against GMZ2 developed in both GMZ2 vaccinated groups.
Conclusions/Significance: Both 30 mg as well as 100 mg intramuscular GMZ2 are immunogenic, well tolerated, and safe in
young, malaria-exposed Gabonese children. This result confirms previous findings in naı¨ve and malaria-exposed adults and
supports further clinical development of GMZ2.
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Introduction
Malaria control relies primarily on case management and the
use of impregnated bednets. Recently, a decline in the incidence of
malaria associated with scaling up of interventions has been
reported in many countries [1], raising hopes that malaria could
be eliminated in these countries [2]. However, before these goals
can be achieved, significant political, economic as well as scientific
hurdles need to be addressed. Malaria vaccines may have an
important role in malaria control and elimination, in part because
they can be readily integrated into existing health care structures.
Two main lines of research on malaria vaccines have resulted in
advanced clinical development programmes, the induction of
immunity against pre-erythrocytic stages, and mimicry of naturally
acquired immunity to clinical malaria through vaccination with
blood stage antigens. GMZ2 is one representative of the second
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group which is currently under clinical development and RTS,S/
AS01 is the most advanced of the first group [3]. Naturally
acquired immunity is not sterile but protects from severe
symptoms and complications, and despite marked genetic and
antigenic variability of the parasite, is remarkably robust. Several
passive transfer experiments showed that antibodies are central to
the development of natural immunity [4,5,6]. Robustness of
naturally-acquired immunity was most convincingly demonstrated
when antibody preparations from one continent (Africa) were used
to inhibit in vivo growth of parasites in malaria patients from
another continent (Asia) [5]. Unfortunately, the mechanism of
protection and the targets of immunity are not known although
several immunological surrogate markers of protection have been
proposed. Analysis of sera from immune adults from endemic
regions, including those from passive transfer experiments, led to
the identification of merozoite surface protein 3 (MSP3) as a
potentially important antigen for the induction of anti-malarial
immunity [7]. Another antigen that elicits antibodies in frequently
exposed individuals is glutamate rich protein (GLURP). High anti-
GLURP titers have been associated with protection from malaria
in several studies [8,9] and it was shown that anti-GLURP
antibodies induce antibody-dependent cellular inhibition (ADCI)
in a way similar to MSP3 [10]. A fusion protein of conserved parts
of both proteins showed good immunogenicity. Since the
presumed mechanism of protection of MSP3 and GLURP is
similar, and partial protection in pre-clinical trials was document-
ed [11], it was decided to develop a MSP3-GLURP fusion protein
for studies in humans naturally exposed to malaria.
GMZ2 is the preparation of a recombinant GLURP27–500-
MSP3212–380 fusion protein, expressed in Lactococcus lactis, and
mixed with the adjuvant aluminium hydroxide. The vaccine is
given intramuscularly as three injections one month apart. The
first trial in humans, in German malaria-naı¨ve adults, showed
good safety, tolerability and immunogenicity of three different
dosing schemes of GMZ2 [12]. Subsequently, a randomized
controlled trial in malaria-exposed Gabonese adults was done,
where the higher dose of GMZ2 (100 mg) was compared to a
control vaccine (rabies vaccine). In this study, the vaccine was well
tolerated and boosted pre-existing immune responses against the
vaccine antigen [13]. The vaccine induced strong responses to
GMZ2 and to GLURP, but responses to MSP3 were low. The
present trial was designed to provide first data on safety and
immunogenicity of 100 mg GMZ2, and a lower dose 30 mg
GMZ2, in malaria-exposed children 1–5 years of age, the group in
which phase IIb efficacy trials would be done.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants and interventions
The study took place from September 2008 to October 2009 at
the Albert Schweitzer Hospital Lambare´ne´, Gabon, an area with
year-round malaria transmission [14]. Healthy children from
Figure 1. Study flow. All participants received the complete course of vaccination and were followed for 4 weeks after the last vaccination. * The
subject lost to follow-up and was in good health when examined after the scheduled Day 365 visit.
doi:10.1371/journal.pone.0022525.g001
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Lambare´ne´ between 1 and 5 years of age were screened and those
who met the inclusion criteria were randomly assigned 1 1 1 to
receive three doses of either rabies vaccine, 30 mg GMZ2 (GMZ2-
30) or 100 mg GMZ2 (GMZ2-100). Vaccine doses were given one
month apart (days 0, 28 and 56) intramuscularly, alternately in the
left or right deltoid muscle. GMZ2 was produced as one clinical
batch following Good Manufacturing Practice (Henogen SA,
Belgium) and provided in aliquots of 12 m. Aluminium hydroxide
(Statens Serum Institut, Denmark) was provided in separate vials
and mixed with the vaccine one hour before administration
following a standard operating procedure in a separate prepara-
tion room equipped with a sterile flow hood. Rabies vaccine
(Verorab, Sanofi Pasteur) was used as control vaccine. Each child
was kept under observation for 30 minutes after vaccination. A
physician examined participants on the day of vaccination and 1,
3, 7, and 14 days after each vaccination. Participants were re-
examined by a physician on Day 84 (one month after the last dose
of vaccine) and on Day 365 (10 months after the last vaccine dose).
Children were visited at home by a field worker 2, 4, 5 and 6 days
after each vaccination and on days 140, 224 and 308 after the first
vaccination to assess health and record the occurrence of adverse
events. A 24-hour phone line was maintained for parents to
contact the study team in the event of any adverse event.
Ethics
Written informed consent was obtained from the parents of
participating children. If the child’s parent or guardian was unable
to read, an impartial witness was present during the informed
consent and signed together with the child’s parent the informed
consent form. The study was approved by the Comite´ d’Ethique
Re´gional Inde´pendant de Lambare´ne´ (CERIL) and the Gabonese
Ministry of Health. A data and safety monitoring board (DSMB)
monitored subject safety during the trial. The study was conducted
according to the Declaration of Helsinki (5th revision) and
International Conference on Harmonization Good Clinical
Practice (ICH-GCP) guidelines.
Objectives and outcomes
The primary objective was to evaluate the safety and
reactogenicity of three injections of either 30 or 100 mg GMZ2
compared to rabies vaccine in the target group for a clinical phase
IIb efficacy trial. As secondary objective, humoral immune
responses were assessed.
Randomization and blinding
A screening list of 39 eligible individuals was sorted on sex and
age; 30 were required for enrolment, so 9 individuals (every 4th
Figure 2. Solicited adverse events. Intensity of local and systemic AE in the 7 days post-vaccination period. Given is the grade of the AE with the
highest intensity at each day of follow up as shading (from grey [no AE] to dark blue [grade 3]). Local grade 2 AEs were (top down) pain, swelling,
swelling, and pruritus at the injection site. Grade 3 reactions were only present as systemic reactions. They consisted of (top down) fever, fever, loss of
appetite, and fever (all fevers were due to upper respiratory infection). All grade 3 AEs were judged not to be related to vaccination. Vaccinations
were given on Days 0, 28, and 56.
doi:10.1371/journal.pone.0022525.g002
Table 1. Baseline characteristics of study participants.
Rabies GMZ2-30 GMZ2-100
Age (years) * 3.5 (1.9, 4.8) 3.5 (2.2, 5.6) 3.5 (1.8, 5.7)
Gender # 5/5 5/5 5/5
Height (cm) * 96 (85, 105) 94 (82, 114) 92 (77, 109)
Weight (kg) * 14.6 (11.4, 18.6) 13.7 (11.0, 21.8) 13.3 (9.6, 17.0)
Hemoglobin (g/dl) * 10.3 (9.3, 11.9) 10.5 (8.6, 11.8) 10.5 (8.7, 11.8)
White blood cells (cells/nl)* 10.9 (8.3, 13.6) 9.6 (7.3, 13.4) 8.6 (6.1, 11.4)
Thrombocytes (cells/nl)* 387 (262, 487) 322 (222, 408) 381 (201, 516)
*mean (min, max), # female/male.
doi:10.1371/journal.pone.0022525.t001
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individual in the sorted list) were excluded to be used as reserves in
case any selected individuals dropped out before the administra-
tion of the first vaccine dose. The 30 individuals in the sorted list
were then allocated to vaccine group using randomly permuted
blocks of 3 individuals per block. If a subject was withdrawn before
vaccine dose 1, they were to be replaced with the reserve nearest in
age. If a subject was withdrawn after vaccine dose 1, they were not
replaced. The randomization list was sent by electronic mail by a
study statistician (PM) to the study pharmacist who prepared
sealed envelopes. A separate sealed envelope of the randomization
codes was kept by the local safety monitor. The study pharmacists
prepared the vaccines in identical opaque syringes; they had no
other role in the trial.
Laboratory analyses
Immunological assays were done as previously described
[12,13] with minor modifications. For antibody measurement,
enzyme linked immunoassays (ELISA) were done. Antigen-specific
antibody concentration was assessed by solving a four-parameter
logistic regression equation fitted to a serial dilution of a serum
pool of highly positive adults according to published procedures
[15]. Therefore antibody data is expressed as fraction of antibody
concentration compared to a positive serum pool prepared from
high responders of a previous clinical trial on GMZ2 [13].
Memory B-cell enzyme linked immunospot assays (ELISPOT)
were done on freshly isolated peripheral blood mononuclear cells
using previously published procedures [12,13]. Anti-GMZ2, anti-
MSP3, and anti-GLURP antibodies were measured by ELISA,
whereas memory B-cell response was assessed by ELISPOT
against the whole vaccine antigen (GMZ2) and anti-IgG as a
positive control.
Statistical methods and sample size
The aim of the trial was to establish safety of the vaccine doses
with respect to very common adverse reactions. In the previous
two clinical trials [12,13] analysis of ten individuals per group
sufficed to detect increases in anti-GMZ2 immune responses. Data
was captured on paper case report forms and transferred to an
electronic database. All analyses were done using Stata v10 and R
v2.12.0. Data analysis followed a statistical analysis plan that was
finalized before unblinding.
For analysis of antibody concentrations, zero values were
considered as left-censored observations, and replaced with a
constant value equal to the smallest non-zero concentration for
that antigen in the dataset. For each antigen, the ratio of the
geometric mean concentration at each time point to the mean
concentration pre-vaccination, was calculated with a 95%
confidence interval. Analysis of covariance was used to compare
humoral responses between the vaccine groups at each time point,
with adjustment for the pre-dose-one value as a covariate, after
transforming to logarithms, and the adjusted difference in means
between vaccine groups was presented as a ratio in the original
measurement scale, with a 95% confidence interval.
As sensitivity analysis the log-transformed area under the curve
(AUC) of antigen-specific IgG concentration against time was
calculated for each subject from day 0 to day 84 and compared
between vaccine groups. This provides a single test for each
antigen to determine whether the vaccine induced an antibody
response. ELISPOT data are given as number of GMZ2-specific
cells per total number of antibody secreting cells (ASC). Non-
parametric methods were used to calculate difference in AUC
between groups in a hierarchical approach: Kruskal-Wallis test for
comparison of the three intervention groups and an exact version
the Wilcoxon-Mann-Whitney test for pairwise comparisons if the
first test rejected the null hypothesis. An estimate of the shift in
location and its 95% confidence interval was calculated using the
method of Bauer [16]. Solicited local adverse events (pain,
swelling, induration, erythema, or pruritis at the injection site, or
contralateral reaction) and general adverse events (fever, irritabil-
ity, drowsiness, loss of appetite, or diarrhoea) were graded as mild,
moderate or severe following the guidelines of the Brighton
Collaboration [17]. The number of local and general adverse
events, and the number of non-solicited adverse events, within 14
days after each dose was tabulated for each vaccine group.
Analyses were by intention to treat.
Table 3. Change in antigen-specific antibody concentration to GMZ2, GLURP and MSP3 after 1, 2 and 3 doses of vaccine.
Antigen GMZ2 GLURP MSP3
Vaccine Rabies GMZ2-30 GMZ2-100 Rabies GMZ2-30 GMZ2-100 Rabies GMZ2-30 GMZ2-100
Day 28 0.12 (0.01,1.1) 2.3 (0.70,7.8) 2.6 (0.74,9.1) 1.1 (0.35,3.1) 2.2 (0.57,8.4) 2.5 (0.56,11) 0.3 (0.07,1.2) 0.46 (0.18,1.2) 0.90 (0.22,3.7)
Day 56 0.21 (0.04,1.0) 17 (6.9,49) 9.5 (2.7,34) 0.90 (0.26,3.1) 13 (3.8,42) 8.6 (1.8,40) 0.50 (0.19,1.3) 1.9 (0.94,3.8) 3.3 (1.2,9.1)
Day 84 1.2 (0.57,2.5) 30 (11,83) 19 (6.1,58) 1.7 (0.62,4.5) 21 (6.4,68) 14 (3.8,56) 1.5 (0.83,2.8) 4.2 (2.4,7.6) 7.1 (2.9,17)
Day 365 1.0 (0.50,2.05) 3.2 (1.5,6.9) 1.1 (0.70,1.8) 1.0 (0.37,2.8) 1.9 (1.1,3.5) 1.0 (0.45,2.2) 0.67 (0.33,1.4) 1.2 (0.71,2.0) 0.83 (0.45,1.5)
Data is given as the ratio of geometric mean IgG concentration (95% confidence interval).
doi:10.1371/journal.pone.0022525.t003
Table 2. Non-solicited adverse events grouped by organ
system, recorded until one month after last vaccination.
Rabies GMZ-30 GMZ-100
Ear 3 0 1
Eye 2 1 2
Fever 0 0 2
Gastrointestinal tract 2 2 0
Malaria 1 0 0
Respiratory tract 22 25 22
Skin 3 5 6
Trauma 2 3 10
Urinary tract 0 0 1
TOTAL 35 36 44
All AEs were of mild intensity besides 2 respiratory tract infections of moderate
intensity in the GMZ2-30 and Rabies group, respectively. All AEs resolved
without sequelae.
doi:10.1371/journal.pone.0022525.t002
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Results
Participants flow and recruitment
Thirty-nine out of 55 children were eligible to participate in the
study (Figure 1). The first subject was enrolled on 13th October
2008 and the last patient’s follow-up ended 14th October 2009. All
participants received their scheduled vaccinations (scheduled on
Days 0, 28 and 56) and were closely monitored up to one month
after the third dose (Day 84), and follow-up continued until Day
365. One participant of the GMZ2-100 group, a 3-year-old boy,
was lost to follow-up at Day 365 due to his relocation from the
area. However, the boy was visited and examined two months
after the intended last clinical visit. His parents did not report any
possible drug-related adverse reaction and he was in good health.
At baseline, participants had similar demographic and labora-
tory characteristics (Table 1). One participant, a 2-year-old boy,
received tetanus vaccine on Day 76 of the study, was excluded
from according to protocol analyses of immunogenicity (not
shown). Nevertheless, the full set of 30 children was considered for
safety and immunological outcomes until Day 84. For analyses
including Day 365, all successfully followed 29 children were
assessed.
Figure 3. Antibody responses. Antibody responses against GMZ2, GLURP, and MSP3 are shown as boxplot in the original measurement scale
(Fraction of positive control).
doi:10.1371/journal.pone.0022525.g003
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Adverse events
During the trial two serious adverse events (SAE) occurred. A 4-
year-old boy was hospitalized because of severe malaria (high
parasitemia and prostration) on Day 53. The child recovered
without sequelae and received the 3rd vaccination on Day 59. The
second SAE occurred in a 3-year-old boy. He presented with fever
and upper respiratory infection on Day 29 and was hospitalized
for diagnostic purposes on Day 30. The child was discharged in
good health on Day 32 without causal treatment and received the
third vaccination as planned. Both SAEs occurred in the GMZ2-
30 group and were not related to vaccination as judged by the
investigators and the DSMB.
All children, except for one 4-year-old boy in the rabies vaccine
group had either local or systemic reactions during the vaccination
period from Day 0 to 2 weeks after the last injection (27 out of 30
with at least one local and 21 out of 30 with at least one systemic
reaction). Local and systemic adverse events were slightly more
common in the GMZ2-100 group (Figure 2) most of these events
were mild in severity. No grade 3 local AE was observed. Within 6
days following vaccination two participants of the rabies and one
participant of the GMZ2-100 and -30 groups experienced local
grade 2 reactions. Four grade 3 systemic reactions were observed
after the second vaccine administration, one case of loss of appetite
in the GMZ2-30 group and three cases of fever ($39uC), one in
each intervention group. All grade 3 fever cases were associated
with upper respiratory infections and resolved without specific
treatment.
Unsolicited adverse events during the trial, were all judged not
to be related to the vaccines. In total, 114 unsolicited AE were
observed: none of severe intensity, two of moderate and 112 of
mild intensity (Table 2). Of note, one 4-year-old boy of the rabies
vaccine group developed mild malaria on Day 32 of the study.
Immunogenicity
The concentration of antibodies to GMZ2, GLURP and MSP3
was low in all three groups before vaccination. In both GMZ2
vaccine groups, antibody concentrations to all three antigens
increased after each vaccination, with small increases after the first
dose and larger increases after the second and third doses (Table 3
and Figure 3). In the GMZ2-30 group, all individuals responded to
vaccination with an increase in anti-GMZ2 antibodies at Day 84,
whereas in the GMZ2-100 group one non-responder was
observed. Confidence intervals for the rises in concentration were
wide reflecting the small sample size (Table 3). Anti-MSP3
antibody concentration measured one month after the third dose
of vaccine was higher in the GMZ2 vaccinated groups, than in the
rabies vaccine group, by 2.7 fold (95%CI: 1.6,4.6) in the GMZ2-
30 group and by 3.8 fold (1.5,9.6) in the GMZ2-100 group (ratios
adjusted for differences in pre-vaccination antibody concentra-
tion). Anti-GLURP antibody concentration was 12 fold higher
(7.2,21) in the GMZ2-30 group than in the rabies vaccine group
and 9.7 fold higher (4.4,22) in the GMZ2-100 group. Anti-GMZ2
antibody concentration was 19 fold higher (11,34) in the GMZ2-
30 group and 16 fold higher (7.4,36) in the GMZ2-100 group.
One year after the first vaccination (Day 365) the concentration
of anti-GMZ2, anti-MSP3 and anti-GLURP antibodies was
similar in the rabies and GMZ2-100 groups while the GMZ2-30
group had a 1.2 (1.1,4.2) fold higher baseline corrected anti-
GMZ2 antibody concentration compared to the rabies group on
Day 365.
AUCs were calculated to examine if a different approach of
analyzing leads to similar conclusions (Table 4). Anti-GMZ2, anti-
GLURP and anti-MSP3 antibody AUCs where higher in the
GMZ2-30 and GMZ2-100 groups as compared to the rabies
vaccinated subjects whereas the GMZ2 groups had similar
reactivity, thus confirming the findings of the primary statistical
approach.
Memory B-cell responses increased upon vaccination with
GMZ2 (Figure 4). No increase in anti-GMZ2 memory B-cell
numbers at Day 84 was detected in 4 children of the GMZ2-30
and 3 children of the GMZ2-100 groups. AUCs were significantly
different between the groups (Kruskal Wallis test; p-value =
0.008). Pairwise comparison showed a shift in location of 44
(4.2,98) GMZ2-specific spots per ASC times Days for the
comparison between rabies and GMZ2-100 AUCs, 49 (7.6,251)
for rabies versus GMZ2-30 and a non-significant 27.4 (2211,45)
for GMZ2-100 versus GMZ-30. There was no evidence of an
association between antigen-specific antibodies and memory B-cell
response (data not shown).
Discussion
Clinical development of malaria vaccines has gained momen-
tum in recent years. Several vaccine candidates have been
evaluated in malaria-exposed individuals but only very few have
proceeded to efficacy trials in endemic countries. Asexual blood
stage vaccines that have been tested for efficacy in naturally
exposed individuals (clinical phase IIb) recently, include AMA-1
[18] and MSP142 (FMP1-AS02A) [19]. Unfortunately, these
malaria vaccine candidates did not protect children in phase II
efficacy trials. Two major difficulties in the selection of potential
vaccine antigens are the lack of a surrogate marker for protection
and the high degree of variability of antigens that are exposed to
the immune system. GMZ2 is one of the latest vaccine candidates
to enter clinical trials. Association studies suggest a prominent role
of both antigens contained in GMZ2 in protection from malaria
and showed partial efficacy in an animal model [11]. In addition,
both antigen fragments used in the vaccine are conserved in
clinical isolates [20,21], which may constitute an advantage over
other candidates. Therefore a clinical development program for
GMZ2 was developed that resulted in the present phase Ib trial to
assess safety and immunogenicity in the target population for a
subsequent clinical phase IIb efficacy trial.
GMZ2 has been developed under the premise that vaccination
schedule should be compatible with the Expanded Program on
Immunization (EPI), although it is being increasingly recognized
that the EPI scheme may be unlikely to induce maximal
immunogenicity. Nonetheless, GMZ2 was well tolerated and
induced a robust immune response in its target population. No
vaccine-related SAEs or grade 3 AEs were observed and all GMZ2
vaccinated participants developed either anti-GMZ2 antibodies or
memory B-cells.
Both the 30 mg and 100 mg GMZ2 induced strong antibody
responses to GLURP, as has been seen with GMZ2 in previous
trials [12,13]. Both groups showed responses to MSP3, in contrast
to the study in Gabonese adults, where there was no evidence of
Table 4. Area under the curve IgG concentration.
Rabies GMZ2-30 GMZ2-100
Anti-GMZ2 6.7 (4.4,10) 65 (39,109) 58 (24,141)
Anti-GLURP 6.9 (5,11) 53 (32,87) 41 (17,103)
Anti-MSP3 13 (10,18) 29 (18,47) 36 (15,88)
Data is given as geometric mean (95% confidence interval) in fraction of
positive control x days.
doi:10.1371/journal.pone.0022525.t004
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responses to MSP3. The rise in anti-MSP3 IgG concentration after
three doses was somewhat greater in the 100 mg group than in the
30 mg group but the trial was not powered to be able to compare
immunogenicity between these two groups, (a much larger trial
would have been required to determine whether 30 mg GMZ2 was
as immunogenic as 100 mg). Considering data from all phase I
trials of GMZ2 [12,13], the 100 mg dose is safe and well tolerated
and was selected for further clinical development, although this
does not rule out the use of other doses in the final product. In
contrast to malaria-naı¨ve German adults [12], antigen-specific IgG
concentrations seemed to decrease by Day 365, but the confidence
intervals were wide and the trial was too small to evaluate
persistence of IgG response. If anti-parasitic immunity can be
induced, it will be important to investigate kinetics of IgG
responses and to consider alternative administration schemes,
doses, or vaccine formulations to improve longevity of responses
and of protection. Such trials will be extraordinarily helpful for
understanding immune response patterns and their role in
protection.
The number of GMZ2 vaccinated subjects is still low (a total of
70 people have been vaccinated with GMZ2, 40 of them with the
100 mdose), therefore it is too early to assess its overall safety with
confidence. Nevertheless, the use of aluminum hydroxide, one of
the most frequently administered molecules in vaccinations, as
the adjuvant was a choice that minimizes safety problems and
therefore the good tolerability is not surprising. We believe that
this is an important issue and should be investigated with more
emphasis in other vaccines that use novel and experimental
adjuvant systems. This is particularly relevant for vaccines
intended for widespread use in young children.
In conclusion, GMZ2 is immunogenic and well tolerated.
Efficacy studies are now needed and a multi-center phase IIb trial
in four countries has been designed to determine whether three
doses of 100 mg GMZ2 can protect children from malaria.
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